- P-ISSN 1225-0163
- E-ISSN 2288-8985
사람혈장 중 베타투 수용체 작용약 테르부탈린의 정량법을 개발하고 밸리데이션을 실시하였다. 혈장시료를 Sep-pak 실리카를 이용하여 고상추출한 후 HPLC로 측정하였다. C18 칼럼을 사용하여 혈장 중의 방해물질로부터 테르부탈린 분획을 분리하여 실리카칼럼으로 보내어 테르부탈린과 내부표준물질을 분리 정량하였다. 두 칼럼은 짧은 실리카 전칼럼이 달린 절환밸부로 연결하여 사용하였다. C18 칼럼의 이동상에 녹아있는 테르부탈린의 분획은 전칼럼에서 농축되어 실리카칼럼으로 보내지고 형광 여기파장 276 nm와 들뜸파장 306 nm로 측정하였다. 이 분석법은 여섯 명의 혈장에서 특이성이 있음을 확인하였다. 혈장 중 테르부탈린 0.4-20.0 ng/mL 농도범위에서 상관계수 0.9999로 양호한 직선성을 나타내었다. 정량한계농도는 0.4 ng/mL 농도로 정밀도가 10.1% 를 나타내었다.
A method was developed and fully validated for the determination of terbutaline, a β2-receptor agonist, in human plasma. Plasma samples were prepared by solid-phase extraction with Sep-Pak silica, followed by high-performance liquid chromatography (HPLC). The terbutaline was pre-separated from the interfering components in plasma on a Luna C18 (2) column, and terbutaline and salbutamol as an internal standard were resolved and determined on a Luna Silica column. The two columns were connected by a switching valve equipped with silica pre-column. The pre-column was used to concentrate the terbutaline in the eluent from the C18 column before back-flushing onto the silica column with fluorescence detection at an excitation/emission wavelength of 276/306 nm. The method was shown to be specific by testing six different human plasma sources. Linearity was established for a concentration range of 0.4-20.0 ng/mL with a correlation coefficient of 0.9999. The lower limit of quantitation was 0.4 ng/mL with a precision of 10.1% as C.V.%.
1. M. T. Acekrmans, J. L. Beckers, F. M. Everaerts and I. G. J. A. Seelen, J. Chromatogr., 590, 341-353 (1992).
2. G. A. Jacobson and G. M. Peterson, J. Pharm. Biomed. Anal., 12, 825-832 (1994).
3. United States Pharmacopeia (USP30) and National formulary (NF 25), United State Pharmacopeial Convention, Rockville, MD (2007).
4. British Pharmacopoeia (BP 2013), British Pharmacopoeia Commission, Market Towers, London (2013).
5. R. A. Clare, D. S. Davies and T. A. Baillie, Biomed. Mass. Spectrom., 6, 31-37 (1979).
6. S. E. Jacobsson, S. Jonsson, C. Lindberg and L. A. Svensson, Biomed. Mass. Spectrom., 7, 265-268 (1980).
7. M. Caban, P. Stepnowski, M. Kwiatkowski, N. Migowska and J. Kumirska, J. Chromatogr. A., 1281, 8110-8122 (2011).
8. V. L. Herring and J. A. Johnson, J. Chromatogr. B., 741, 307-312 (2000).
9. Y. Q. Xia, D. Q. Liu and R. Bakhtiar, Chirality, 14, 742-749 (2002).
10. T. Zhou, T. Zhao, Q. Cheng, S. Liu, L. Xu and W. Tan, Biomed. Chromatogr., 28, 994-1002 (2014).
11. P. T. McCarthy, S. Atwal, A. P. Sykes and J. G. Ayres, Biomed. Chromatogr., 7, 25-28 (1993).
12. K. H. Kim, H. J. Kim, S. P. Hong and S. D. Shin, Arch. Pharm. Res., 23(5), 441-445, (2000).
13. Y. Arai, T. Fukushima, M. Shirao, X. Yang and K. Imai, Biomed. Chromatogr., 14, 118-124 (2000).
14. R. Wyss, F. Bucheli and W. Philipp, J. Chromatogr. A., 870, 189-198 (2000).
15. K. H. Kim, H. J. Kim, J. H. Kim and S. D. Shin, J, Chromatpgr. B., 751, 69-77 (2001).
16. Y. Zhang and Z. R. Zhang, J. Chromatpgr. B., 805, 211-214 (2004).